Iranian general populations' and health care providers' preferences for benefits and harms of statin therapy for primary prevention of cardiovascular disease
- PMID: 33148227
- PMCID: PMC7640674
- DOI: 10.1186/s12911-020-01304-w
Iranian general populations' and health care providers' preferences for benefits and harms of statin therapy for primary prevention of cardiovascular disease
Abstract
Background: The use of statins for primary prevention of cardiovascular diseases is associated with different benefit and harm outcomes. The aime of this study is how important these outcomes are for people and what people's preferences are.
Methods: We conducted a preference-eliciting survey incorporating a best-worst scaling (BWS) instrument in Iran from June to November 2019. The relative importance of 13 statins-related outcomes was assessed on a sample of 1085 participants, including 913 general population (486 women) and 172 healthcare providers from the population covered by urban and rural primary health care centers. The participants made trade-off decisions and selected the most and least worrisome outcomes concurrently from 13 choice sets; each contains four outcomes generated using the balanced incomplete block design.
Results: According to the mean (SD) BWS scores, which can be (+ 4) in maximum and (- 4) in minimum, in the general population, the most worrisome outcomes were severe stroke (3.37 (0.8)), severe myocardial infarction (2.71(0.7)), and cancer (2.69 (1.33)). While myopathy (- 3. 03 (1.03)), nausea/headache (- 2.69 (0.94)), and treatment discontinuation due to side effects (- 2.24 (1.14)) were the least worrisome outcomes. Preferences were similar between rural and urban areas and among health care providers and the general population with overlapping uncertainty intervals.
Conclusion: The rank of health outcomes may be similar in various socio-cultural contexts. The preferences for benefits and harms of statin therapy are essential to assess benefit-harm balance when recommending statins for primary prevention of cardiovascular diseases.
Keywords: Benefit harm outcomes; Cardiovascular disease; Preferences; Primary prevention; Statins.
Conflict of interest statement
The authors declare that there is no conflict of interest in this study.
Figures


Similar articles
-
Optimal risk thresholds for prescribing statins as primary prevention of cardiovascular disease in Iranian general population: a benefit-harm modelling study.BMC Cardiovasc Disord. 2024 Oct 18;24(1):575. doi: 10.1186/s12872-024-04242-x. BMC Cardiovasc Disord. 2024. PMID: 39425029 Free PMC article.
-
Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts.BMC Cardiovasc Disord. 2018 May 18;18(1):97. doi: 10.1186/s12872-018-0838-9. BMC Cardiovasc Disord. 2018. PMID: 29776337 Free PMC article.
-
Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study.BMC Cardiovasc Disord. 2020 Sep 17;20(1):418. doi: 10.1186/s12872-020-01697-6. BMC Cardiovasc Disord. 2020. PMID: 32942999 Free PMC article.
-
Women Versus Men: Is There Equal Benefit and Safety from Statins?Curr Atheroscler Rep. 2016 Feb;18(2):6. doi: 10.1007/s11883-016-0562-9. Curr Atheroscler Rep. 2016. PMID: 26782824 Review.
-
Discontinuation of Statins: What Are the Risks?Curr Atheroscler Rep. 2016 Jul;18(7):41. doi: 10.1007/s11883-016-0596-z. Curr Atheroscler Rep. 2016. PMID: 27221503 Review.
Cited by
-
Developing Tools for the Efficient Design of Health Preference Studies: Taxonomy of Attributes and Prototype of an Attribute Library.Patient. 2025 Jul 3. doi: 10.1007/s40271-025-00751-9. Online ahead of print. Patient. 2025. PMID: 40610706 Review.
-
Ethnicity based differences in statin use and hypercholesterolemia control among patients with premature coronary artery disease-results of I-PAD study.Int J Cardiol Cardiovasc Risk Prev. 2023 Jan 14;16:200168. doi: 10.1016/j.ijcrp.2023.200168. eCollection 2023 Mar. Int J Cardiol Cardiovasc Risk Prev. 2023. PMID: 36874039 Free PMC article.
-
Optimal risk thresholds for prescribing statins as primary prevention of cardiovascular disease in Iranian general population: a benefit-harm modelling study.BMC Cardiovasc Disord. 2024 Oct 18;24(1):575. doi: 10.1186/s12872-024-04242-x. BMC Cardiovasc Disord. 2024. PMID: 39425029 Free PMC article.
References
-
- Sarrafzadegan N, Mohammmadifard N: Cardiovascular Disease in Iran in the Last 40 Years: Prevalence, Mortality, Morbidity, Challenges and Strategies for Cardiovascular Prevention. Arch Iran Med. 2019, 22(4):204–210, https://www.ncbi.nlm.nih.gov/pubmed/31126179 - PubMed
-
- Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH et al: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014, 63(25 Pt B):2889–2934. doi:10.1016/j.jacc.2013.11.002 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical